

1 **Title:** Prevalence and Relationship of Rest Tremor and Action Tremor in Parkinson's  
2 Disease.

3  
4 **Authors:** Deepak K. Gupta, MD<sup>1,2,\*</sup>, #; Massimo Marano, MD<sup>3,\*</sup>; Cole Zweber, MS<sup>2</sup>; James  
5 T. Boyd, MD<sup>1,2</sup>; Sheng-Han Kuo<sup>4</sup>, MD

6  
7 <sup>1</sup>Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington,  
8 Vermont, USA

9 <sup>2</sup>Neurology, Binter Center for Parkinson's Disease and Movement Disorders, University of  
10 Vermont Medical Center, Burlington, Vermont, USA

11 <sup>3</sup>Neurology, Neurophysiology and Neurobiology unit, Department of Medicine, University  
12 Campus Bio-Medico of Rome, Italy

13 <sup>4</sup>Neurology, Columbia University, New York City, New York, USA.

14  
15 \* authors with equal contributions

16 #Corresponding author

17  
18 **Corresponding author:**

19 Deepak K. Gupta, MD

20 [drdkgupta@gmail.com](mailto:drdkgupta@gmail.com)

21 1 South Propsect St, Old Hall 2-126B

22 Burlington, Vermont 05401

23

24 **Manuscript word count:** 2021/2500.

25

26 **Abstract:** 237/200

27

28 **Figures:** 2/2

29

30 **Tables:** 4/2

31

32 **References:** 22/50.

33

34 **Keywords:** Tremor, Parkinson's Disease, Rest Tremor, Action Tremor, PPMI, BioFIND,

35 PDBP

36

37 **Funding sources:** Authors deny any funding source for the present study.

38

39 **Author disclosures:**

40 Dr Deepak Gupta – received research grant from the Binter Center, UVM Medical

41 Center Foundation, Larner College of Medicine Team Academy and Parkinson Study

42 Group.

43 Dr Massimo Marano – served as a consultant and/or scientific advisor for AbbVie and

44 Allergan, received research grants by the “Alberto Sordi” foundation for elderly.

45 Cole Zweber – None.

46 Dr James Boyd –served as a consultant and/or scientific advisor for AbbVie Inc, Teva,  
47 Neurocrine, InTrance and Medical Education Resources. He has received research  
48 support from the NIH/NINDS, Biotie, Cure Huntington's Disease Initiative, Vaccinex,  
49 Teva, AbbVie Inc, NeuroDerm, Roche/Genentech, Neurocrine, and Revance.

50 Dr Sheng-Han Kuo – received funding from the National Institutes of Health: NINDS  
51 #R01 NS104423 (principal investigator), NINDS #R03 NS114871 (principal  
52 investigator), Brain Research Foundation, National Ataxia Foundation, Parkinson's  
53 Foundation, and International Essential Tremor Foundation.

54 **Abstract**

55

56 Background: Despite the significance of tremor in Parkinson's disease (PD) diagnosis,  
57 classification, and patient's quality of life, there is a relative lack of data on prevalence  
58 and relationship of different tremor types in PD.

59

60 Methods: The presence of rest tremor (RT) and action tremor (AT; defined as  
61 combination of both postural and kinetic tremor) was determined and RT severity was  
62 defined using the Movement Disorders Society Unified Parkinson's Disease Rating  
63 Scale (MDS-UPDRS) at baseline in the Progression Marker Initiative (PPMI, n=423), the  
64 Fox Investigation for New Discovery of Biomarkers (BioFIND, n=118) and the  
65 Parkinson's Disease Biomarkers Program (PDBP, n=873) cohorts.

66

67 Results: Across baseline data of all three cohorts, RT prevalence (58.2%) was higher  
68 than AT prevalence (39.0%). Patients with RT had significantly higher (Chi-square test,  
69  $p < 0.05$ ) prevalence of AT compared to patients without RT in the PPMI (40.0% versus  
70 30.1%), BioFIND (48.0% versus 40.0%) and PDBP (49.9% versus 21.0%) cohorts.

71 Furthermore, patients with AT had significantly (Student t-test,  $p < 0.05$ ) higher RT  
72 severity than those without AT in PPMI ( $5.7 \pm 5.4$  versus  $3.9 \pm 3.3$ ), BioFIND,  $6.4 \pm 6.3$   
73 versus  $3.8 \pm 4.4$ ) and PDBP ( $6.4 \pm 6.6$  versus  $3.7 \pm 4.4$ ) cohorts.

74

75 Discussion: The RT is the most frequent tremor type and present in more than half of  
76 the PD patients. However, AT is also present in nearly one-third of the PD patients. Our  
77 results also indicate that RT and AT may have cross-interactions in PD.

78 **Manuscript:**

79

80 Introduction:

81

82 Tremor has been defined as a rhythmic and oscillatory involuntary movement with varied  
83 phenomenology, which can be classified based on several parameters, such as body  
84 parts, frequency and activation state[1]. The latest consensus classification by the  
85 Movement Disorders Society (MDS) classifies tremor using a two-axis approach based on  
86 clinical features and etiology, which are then subclassified into multiple subcategories.  
87 Within the category of clinical feature axis and its subcategory of tremor characteristics,  
88 tremor is subclassified based on activation characteristics into rest tremor (RT) and action  
89 tremor (AT) [2]. The RT has been defined as a tremor in a body part that is not voluntarily  
90 activated, assessed when the patient is attempting to relax and is given adequate  
91 opportunity to relax the affected body part. Whereas the MDS classification of RT is a  
92 singular definition, AT is further sub-divided into postural tremor, kinetic tremor and  
93 isometric tremor. AT has been defined as a tremor occurring in a body part while  
94 voluntarily maintaining a position against gravity (postural tremor), during any voluntary  
95 movement (kinetic tremor), or during muscle contraction against a rigid stationary object  
96 (isometric tremor) [2].

97

98 Although RT is one of the cardinal features of Parkinson's Disease (PD), PD patients are  
99 also observed to have postural tremor, kinetic tremor or both [3, 4]. In addition to being one  
100 of the most visual symptoms of PD, tremor is also ranked as one of the most troubling

101 symptoms by PD patients[5]. Moreover, tremor impairs several physical and psychological  
102 quality of life domains in PD patients, similar to essential tremor patients as assessed with  
103 Quality of Life in Essential Tremor (QUEST) questionnaire[6]. Importantly, presence of  
104 tremor is also used to classify PD into tremor-dominant (TD), indeterminate (IND) and  
105 postural instability and gait difficulty (PIGD) subtypes[7], which have been linked with  
106 different rates of disease progression [8]. Specifically, a total of 8 and 11 tremor items from  
107 Unified Parkinson Disease Rating Scale (UPDRS) or MDS-UPDRS scales are used to  
108 calculate tremor score, which is then used in conjunction with the postural instability/gait  
109 difficulty (PIGD) score, for computing these subtypes[7].

110  
111 Despite such significance of tremor in PD, descriptions of prevalence of basic tremor types  
112 (RT, postural tremor, kinetic tremor) and relationship of RT with AT in PD are currently  
113 limited [3, 9-12], as summarized in table 1. Here, we aimed to describe the prevalence of  
114 basic tremor types, and the relationship of RT with AT in three large cohorts of PD  
115 patients, including the Parkinson Progression Marker Initiative (PPMI)[13], The Fox  
116 Investigation for New Discovery of Biomarkers (BioFIND)[14], and the Parkinson's Disease  
117 Biomarkers Program (PDBP) [15].

118  
119 **Methods:**

120  
121 The PPMI, BioFIND and PDBP are multi-center, observational studies, designed to  
122 accelerate research in PD, especially biomarkers discovery, through collection of clinical,  
123 biospecimen and other relevant data, such as imaging, by making the data available to

124 researchers in an open-access manner through their respective portals. The PPMI is an  
125 international, longitudinal study of early stage PD patients (n= 423), recruited within 6  
126 months from initial diagnosis and not on dopaminergic treatment, and healthy controls (n =  
127 196). The BioFIND is a cross-sectional study of moderate to advanced stage PD patients  
128 (n = 118) on dopaminergic treatment and healthy controls (n = 88). The PDBP is a  
129 longitudinal study of primarily early to advanced stages PD patients (n= = 882), with most  
130 patients on dopaminergic treatment and healthy controls (n= = 549), in addition to patients  
131 with other related clinical diagnosis (n= = 168, e.g., atypical parkinsonian disorder,  
132 essential tremor). A summary of relevant demographics and clinical features of these three  
133 cohorts is presented in table 2, while more details have been described in the respective  
134 cohorts elsewhere [13-15].

135  
136 We chose to compare the PPMI, BioFIND and PDPB cohorts of PD patients for this study  
137 for a variety of reasons: large number of PD patients in each cohort; subjects recruited in  
138 each cohort by movement disorders specialists; data were available on open-access basis;  
139 and, a wide range of severity of disease, ranging from drug-naïve PD patients in the PPMI  
140 cohort, moderately advanced PD patients on dopaminergic treatment (with MDS-UPDRS  
141 captured in on-state on baseline visit and off-state in follow-up visit) in the BioFIND cohort,  
142 and all stages of PD severity in cohort with majority being on dopaminergic treatment (with  
143 MDS-UPDRS irrespective of off-state or on-state) in the PDBP cohort.

144  
145 Baseline visit data of the PD patients (n = 423 for PPMI, n = 118 for BioFIND, n = 873 for  
146 PDBP) were accessed as of January 22, 2020 from the PPMI (<https://www.ppmi-info.org>)

147 and Accelerating Medicine Partnership in Parkinson's Disease (AMP PD) databases  
148 (<https://amp-pd.org/>). For the BioFIND cohort, the MDS-UPDRS part III data from  
149 baseline visit (on-state) were used by default for all calculations, while the follow-up visit  
150 data (off-state; 14 days after the baseline visit) were used for comparison separately.

151  
152 The three basic tremor types, specifically, RT, postural tremor, and kinetic tremor were  
153 captured by value of  $\geq 1$  on items 3.17 (*rest tremor amplitude*), 3.15 (*postural tremor of*  
154 *the hands*), and 3.16 (*kinetic tremor of hands*), respectively, from part III (motor) of the  
155 MDS-UPDRS in all three cohorts. For the purpose of this study, we defined AT to include  
156 both postural and kinetic, rather than postural or kinetic tremor, as former approach yields  
157 higher specificity and avoids false positives, given that re-emergent rest tremor can be  
158 frequently mistaken as postural tremor[16]. We also defined RT severity (range 0 – 80) by  
159 adding five sub-items of RT (3.17) and then multiplying the sum with item 3.18 (*constancy*  
160 *of rest tremor*) (3.18) from part III (motor) of the MDS-UPDRS. We also assessed the  
161 perception of tremor by patient using item 2.10 (*Over the past week, have you usually had*  
162 *shaking or tremor?*) from part II of the MDS-UPDRS.

163  
164 We first analyzed the average prevalence of RT (irrespective of postural or kinetic tremor),  
165 pure RT (with neither postural tremor or kinetic tremor), AT (irrespective of RT), pure AT  
166 (with no RT), postural tremor (irrespective of RT or kinetic tremor), pure postural tremor  
167 (with neither RT or kinetic tremor), kinetic tremor (irrespective of RT or postural tremor),  
168 pure kinetic tremor (with neither RT or postural tremor), no tremor (neither RT, postural  
169 tremor or kinetic tremor), any tremor (any of three basic tremor types) and all tremor (all



170 three basic tremor types), and distribution of perception of tremor across baseline data of  
171 the three cohorts and in each individual cohort. We then tested the hypothesis that  
172 prevalence RT and AT are not independent of each other, such that the severity of RT  
173 would be higher in PD patients with AT versus without AT, in individual cohorts. Finally, we  
174 also compared prevalence of RT, AT, postural tremor, kinetic tremor, any tremor and all  
175 tremor in off-state and on-state in the BioFIND cohort. Statistical testing was performed  
176 using SPSS version 26 with appropriate statistical tests at a significance level ( $p < 0.05$ ).

177

178 Results:

179

180 The average prevalence of RT and pure RT was 58.2% and 14.5 %, respectively. In  
181 contrast, the average prevalence of AT and pure AT were 36.6% and 9.6%, respectively.  
182 The average prevalence of postural tremor and pure postural tremor was 49.7% and 4.0  
183 %, respectively. The average prevalence of kinetic tremor and pure kinetic tremor was  
184 52.3% and 8.1 %, respectively. The average prevalence of patients with no tremor, any  
185 tremor and all tremor were 19.9%, 79.9%, and 26.9%, respectively. Figure 1 provides a  
186 summary of these results using a diagram. Table 3 summarizes these results in each  
187 individual cohort.

188

189 As for average perception of tremor by the patient over past week, 19.5% of the patients  
190 reported having no tremor, while 52.8%, 21.4%, 5.3% and 1.0%, reported having slight,  
191 mild, moderate and severe tremor, respectively. Table 4 summarizes these results in each

192 individual cohort. Conversely, on average 79.5% patients reported having any shaking or  
193 tremor (slight, mild, moderate or severe) over past week.

194  
195 We also found that patients with RT versus without RT consistently had a significantly  
196 higher (Chi-square test) proportion of AT in the PPMI (40.0% versus 30.1%,  $p = 0.049$ ), in  
197 the BioFIND (48.0% versus 40.0%,  $p = 0.008$ ) and PDBP (49.9% versus 21.0%,  $p = 0.000$ )  
198 cohorts, respectively. Based on these observations, we postulated that PD patients might  
199 develop AT after RT becomes severe, or conversely, PD patients with AT would have  
200 higher severity of RT compared to patients without AT. In support of this hypothesis, we  
201 found that the severity of RT was significantly higher (Student's t-test) in patients with AT  
202 than patients without AT in the PPMI ( $5.7 \pm 5.4$  versus  $3.9 \pm 3.3$ ,  $p = 0.000$ ), BioFIND ( $6.4$   
203  $\pm 6.3$  versus  $3.8 \pm 4.4$ ,  $p = 0.000$ ) and PDBP ( $6.4 \pm 6.6$  versus  $3.7 \pm 4.4$ ,  $p = 0.000$ )  
204 cohorts, respectively.

205  
206 In the BioFIND cohort (in which patients were examined in on-state on baseline visit and  
207 off-state in second visit), we found that the prevalence of RT, AT, postural tremor, kinetic  
208 tremor, any tremor and all tremor were significantly ( $p < 0.05$ , Chi-square test) higher in  
209 off-state, compared to on-state (figure 2). The RT severity was also higher in off-state  
210 ( $5.87 \pm 8.94$ ) compared to on-state ( $4.04 \pm 6.76$ ), however, this difference did not reach  
211 statistical significance ( $p=0.051$ ).

212  
213 Discussion:

214

215 Our study results indicate that across the PPMI, BioFIND and PDBP cohorts, although RT  
216 has the highest prevalence (58.2%) in PD, AT can also be present in a sizable number  
217 (36.2%) of PD patients, which is in line with similar literature[11, 12, 17]. In comparison, a  
218 large majority (79.5%) of the patients self-report having tremor. Our study results also  
219 indicate all tremor types are reduced by dopaminergic treatment, which is consistent with  
220 the traditionally held view on the influence of levodopa and dopamine agonist on tremor in  
221 PD[18, 19].

222  
223 We also found that the PD patients with RT had significantly higher prevalence of AT in all  
224 three cohorts. Moreover, we found that the patients with AT, compared to patients without  
225 AT, had more severe RT in all three cohorts, similar to findings reported in previous  
226 studies[11, 12]. These findings together demonstrate that AT could be a part of broader  
227 tremor syndrome of PD. Furthermore, these findings are supported by functional  
228 neuroimaging and electrophysiology studies demonstrating cross-interactions between  
229 basal ganglia and cerebellothalamic circuitry in mediating tremor in PD [20, 21]. The  
230 presence of re-emergent RT or a comorbid alternative tremor disorder (such as essential  
231 tremor) could, at least in part, explain these findings. It is worth noting that MDS-UPDRS  
232 scale does not distinguish between postural tremor and re-emergent rest tremor mimicking  
233 postural tremor, and such distinction can only definitely be made with electrophysiological  
234 analysis [16].

235  
236 One of the limitations of our study was that the data used for defining prevalence of  
237 different types of tremor were collected by multiple investigators in the PPMI, BioFIND and

238 PDBP cohorts. However, these data are considered valid as the clinical examination for  
239 recording presence of tremor were done as part of the standardized MDS-UPDRS by  
240 trained movement disorders specialists in all three of these studies conducted at  
241 internationally recognized movement disorders centers. Another limitation was that we  
242 could not include isometric tremor in defining AT, which was unavoidable since the MDS-  
243 UPDRS scale does not capture isometric tremor. It is also worth noting that MDS-UPDRS  
244 does not capture postural and kinetic tremor in lower limbs or head, unlike RT, which is  
245 captured in upper limbs, lower limbs and lip / jaw.

246  
247 The presence of RT is not mandatory for a diagnosis of PD, which is supported by our data  
248 demonstrating absence of any tremor and presence of pure AT in nearly one-fifth and one-  
249 tenth of all patients across the PPMI, BioFIND and PPMI cohorts. These observations  
250 have implications in clinical practice and research enrollment, where the presence of  
251 patients either without tremor or with multiple tremor subtypes potentially lead to diagnostic  
252 delay, ambiguity and uncertainty. For example, different patterns of basic tremor types  
253 have been shown to improve differential diagnosis of PD from essential tremor[22]. All  
254 together, these results provide further evidence that PD tremor is highly heterogenous and  
255 its correct phenotypic classification in PD will be essential in optimizing diagnostic,  
256 therapeutic and prognostic approaches.

257 **Acknowledgement:**

258

259 PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for  
260 Parkinson’s Research and funding partners, including AbbVie, Allergan, Avid, Biogen,  
261 BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genetech, GSK,  
262 Lilly, Lundbeck, Merk, MSD, Pfizer, Piramidal, Prevail, Roche, Sanofi Genzyme,  
263 Servier, Takeda, Teva, UCB, Verily, Voyager, Golub Capital.

264 Data used in the preparation of this article were also obtained from the AMP PD  
265 Knowledge Platform. For up-to-date information on the study, <https://www.amp-pd.org>."

266 AMP PD – a public-private partnership – is managed by the FNIH and funded by  
267 Celgene, GSK, the Michael J. Fox Foundation for Parkinson’s Research, the National  
268 Institute of Neurological Disorders and Stroke, Pfizer, Sanofi, and Verily."

269

270 **References:**

- 271
- 272 1. Louis, E.D., *Tremor*. Continuum (Minneap Minn), 2019. **25**(4): p. 959-975.
  - 273 2. Bhatia, K.P., et al., *Consensus Statement on the classification of tremors. from*  
274 *the task force on tremor of the International Parkinson and Movement Disorder*  
275 *Society*. *Mov Disord*, 2018. **33**(1): p. 75-87.
  - 276 3. Pasquini, J., et al., *Progression of tremor in early stages of Parkinson's disease:*  
277 *a clinical and neuroimaging study*. *Brain*, 2018. **141**(3): p. 811-821.
  - 278 4. Luo, L., et al., *Motor phenotype classification in moderate to advanced PD in*  
279 *BioFIND study*. *Parkinsonism Relat Disord*, 2019. **65**: p. 178-183.
  - 280 5. Heusinkveld, L.E., et al., *Impact of tremor on patients with early stage*  
281 *Parkinson's disease*. *Frontiers in neurology*, 2018. **9**: p. 628.
  - 282 6. Tröster, A.I., et al., *Quality of life in Essential Tremor Questionnaire (QUEST):*  
283 *development and initial validation*. *Parkinsonism & related disorders*, 2005. **11**(6):  
284 p. 367-373.
  - 285 7. Stebbins, G.T., et al., *How to identify tremor dominant and postural instability/gait*  
286 *difficulty groups with the movement disorder society unified Parkinson's disease*  
287 *rating scale: comparison with the unified Parkinson's disease rating scale*.  
288 *Movement Disorders*, 2013. **28**(5): p. 668-670.
  - 289 8. Rajput, A.H., et al., *Course in Parkinson disease subtypes: A 39-year*  
290 *clinicopathologic study*. *Neurology*, 2009. **73**(3): p. 206-12.
  - 291 9. Rajput, A., B. Rozdilsky, and L. Ang, *Occurrence of resting tremor in Parkinson's*  
292 *disease*. *Neurology*, 1991. **41**(8): p. 1298-1298.
  - 293 10. Hughes, A.J., et al., *A clinicopathologic study of 100 cases of Parkinson's*  
294 *disease*. *Archives of neurology*, 1993. **50**(2): p. 140-148.
  - 295 11. Louis, E.D., et al., *Clinical correlates of action tremor in Parkinson disease*.  
296 *Archives of neurology*, 2001. **58**(10): p. 1630-1634.
  - 297 12. Gigante, A., et al., *Action tremor in Parkinson's disease: frequency and*  
298 *relationship to motor and non-motor signs*. *European Journal of Neurology*, 2015.  
299 **22**(2): p. 223-228.
  - 300 13. Parkinson Progression Marker, I., *The Parkinson Progression Marker Initiative*  
301 *(PPMI)*. *Prog Neurobiol*, 2011. **95**(4): p. 629-35.
  - 302 14. Kang, U.J., et al., *The BioFIND study: Characteristics of a clinically typical*  
303 *Parkinson's disease biomarker cohort*. *Mov Disord*, 2016. **31**(6): p. 924-32.
  - 304 15. Rosenthal, L.S., et al., *The NINDS Parkinson's disease biomarkers program*.  
305 *Mov Disord*, 2016. **31**(6): p. 915-23.
  - 306 16. Dirkx, M.F., et al., *The nature of postural tremor in Parkinson disease*. *Neurology*,  
307 2018. **90**(13): p. e1095-e1103.
  - 308 17. Louis, E.D., et al., *Risk of action tremor in relatives of tremor-dominant and*  
309 *postural instability gait disorder PD*. *Neurology*, 2003. **61**(7): p. 931-936.
  - 310 18. Tedeschi, G., et al., *Tremor in Parkinson disease: acute response to oral*  
311 *levodopa*. *The Italian Journal of Neurological Sciences*, 1990. **11**(3): p. 259-263.
  - 312 19. Elble, R.J., *Tremor and dopamine agonists*. *Neurology*, 2002. **58**(suppl 1): p.  
313 S57-S62.

- 314 20. Dirkx, M.F., et al., *The Cerebral Network of Parkinson's Tremor: An Effective*  
315 *Connectivity fMRI Study*. J Neurosci, 2016. **36**(19): p. 5362-72.
- 316 21. Muthuraman, M., et al., *Cerebello-cortical network fingerprints differ between*  
317 *essential, Parkinson's and mimicked tremors*. Brain, 2018. **141**(6): p. 1770-1781.
- 318 22. di Biase, L., et al., *Tremor stability index: a new tool for differential diagnosis in*  
319 *tremor syndromes*. Brain, 2017. **140**(7): p. 1977-1986.
- 320

321

322 **Table 1:** Summary of previous studies reporting tremor prevalence

<b>Variable</b>	<b>Rajput et al. 1991</b>	<b>Hughes et al. 1993</b>	<b>Louis et al. 2001</b>	<b>Gigante et. al. 2014</b>	<b>Pasquini et al. 2018</b>
Study design	Longitudinal, neuropathologic	Longitudinal, neuropathologica	Cross- sectional clinical	Cross- sectional clinical	Longitudina clinical
Disease duration (years)	NR	13.1 ± 6.3	7.9 ± 5.1	5.2 ± 3.8	2.56 ± 0.56
Tremor assessment method	Visual inspectio	PDSBB form	WHIGET Tremor Rating Scale	UPDRS	MDS-UPDR
Sample size	30	100	197	237	378
Any tremor prevalence	NR	69%	NR	NR	87.8%
Rest tremor prevalence	100%	NR	NR	83.12%	69.6%
Action tremor prevalence	NR	NR	93.4%	46%	NR
Postural tremor prevalence	NR	NR	NR	NR	52.1%
Kinetic tremor	NR	NR	NR	NR	51.6%



prevalence					
------------	--	--	--	--	--

323

324 **Table 1 legend:** Not reported (NR), Unified Parkinson Disease Rating Scale (UPDRS),

325 Washington Heights-Inwood Genetic Study of ET (WHIGET), Parkinson's Disease Society

326 Brain Bank (PDSB). The study by Pasquini et. al. used the Parkinson Progression Marker

327 Initiative (PPMI) data and also reported on prevalence of difference tremor types at 2-

328 years follow-up as following: any tremor 83.9%, rest tremor 67.9%, postural tremor 49.5%,

329 and kinetic tremor 46.8%.

330

331

332 **Table 2:** Summary of relevant demographics and clinical features of the PPMI, BioFIND  
333 and PDBP cohorts.

Variable	PPMI (n=423)	BioFIND (n=118)	PDBP (n=874)
Gender (Male / Female)	146 / 277	62.7%	563 / 319
Age (mean $\pm$ standard deviation)	61.6 $\pm$ 9.7	68.0 $\pm$ 6.5	64.3 $\pm$ 9.1
Disease duration	5.85 $\pm$ 7.5	8.5 $\pm$ 3.2	7.2 $\pm$ 7.5*
% on Dopamine Treatment	0	100%	90.8%

334 **Table 2 legend:** Parkinson Progression Marker Initiative (PPMI), The Fox Investigation for  
335 New Discovery of Biomarkers (BioFIND) and Parkinson's Disease Biomarkers Program  
336 (PDBP). \* this value was taken from original description of the PDBP cohort for 449  
337 Parkinson's disease subjects.

338

339

340 **Table 3:** Distribution of prevalence of different types and combinations of tremor in each of  
341 three cohorts.

<b>Tremor Type</b>	<b>PPMI (n=423)</b>	<b>BioFIND (n=118)</b>	<b>PDBP (n=874)</b>
Rest tremor	290 (68.6%)	75 (63.6%)	459 (52.0%)
Pure rest tremor	87 (20.6%)	15 (12.7%)	104 (11.8%)
Action tremor	156 (36.9%)	46 (39.0%)	316 (35.8%)
Pure action tremor	40 (9.5%)	10 (8.5%)	87 (9.9%)
Postural tremor	223 (52.7)	69 (58.5%)	412 (46.7%)
Pure Postural tremor	18 (4.3%)	8 (6.8%)	31 (3.5%)
Kinetic tremor	217 (51.3%)	61 (51.7%)	463 (52.5%)
Pure kinetic tremor	23 (5.4%)	6 (5.1%)	86 (9.8%)
No tremor	52 (12.3%)	19 (16.1%)	211 (23.9%)
Any tremor	371 (87.7%)	99 (83.9%)	663 (75.2%)
All tremor	116 (27.4%)	36 (30.5%)	229 (26.0%)

342  
343 **Table 3 legend:** Parkinson Progression Marker Initiative (PPMI), Fox Investigation for New  
344 Discovery of Biomarkers (BioFIND), Parkinson's Disease Biomarkers Program (PDBP).

345

346

347 **Table 4:** Distribution of perception of tremor in each of three cohorts.

<b>Variable</b>	<b>PPMI (n=422)</b>	<b>BioFIND (n = 118)</b>	<b>PDBP (n=826)</b>
No tremor	59 (14.0%)	24 (20.3%)	183 (22.1%)
Subtle tremor	282 (66.8%)	59 (50.0%)	380 (46.0%)
Mild tremor	73 (17.3%)	30 (25.4)	189 (22.9%)
Moderate tremor	7 (1.7%)	4 (3.4%)	62 (7.5%)
Severe	1 (0.2%)	1 (0.8%)	12 (1.5%)


348

349 **Table 4 legend:** Movement Disorders Society Unified Parkinson's Disease Rating Scale  
350 (MDS-UPDRS).

351

352 **Figure 1:** Average prevalence of different tremor types and their combinations across  
353 baseline data of the PPMI, BioFIND and PDBP cohorts.

354



355


356

357 **Figure 1 legend.** Parkinson Progression Marker Initiative (PPMI), The Fox Investigation  
358 for New Discovery of Biomarkers (BioFIND) and Parkinson's Disease Biomarkers Program  
359 (PDBP). Size of the circles are not indicative of the prevalence magnitude.

360

361

362 **Figure 2:** Changes in tremor prevalence from off-state to on-state in the BioFIND cohort.



363

364 **Figure 2 legend** Fox Investigation for New Discovery of Biomarkers (BioFIND). On-state

365 data were obtained from the baseline visit; off-state data were obtained by the follow-up

366 visit (14 days after the baseline). \*p<0.05, Chi-Square test.